Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years
BackgroundIn Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients.Research DesignThe research presented in this...
Main Authors: | Aneta Mela, Łukasz A. Poniatowski, Bartłomiej Drop, Marzena Furtak-Niczyporuk, Janusz Jaroszyński, Witold Wrona, Anna Staniszewska, Jan Dąbrowski, Anna Czajka, Beata Jagielska, Monika Wojciechowska, Maciej Niewada |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01123/full |
Similar Items
-
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01) -
New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01) -
Generic Drug Pricing and Substitution in Private Drug Plans in Canada
by: Ismail, Ethar
Published: (2014) -
Generic Drug Pricing and Substitution in Private Drug Plans in Canada
by: Ismail, Ethar
Published: (2014) -
What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)